Real-World Unmet Needs in Patients With HER2-Negative Advanced Gastric, Gastro-Esophageal or Esophageal Adenocarcinoma Receiving First-Line Treatment Globally
Moderator
Jin Gu, PhD, Gilead Sciences, Livingston, NJ, United States
Speakers
Jaffer Ajani; Florian Lordick; Daniel Koralek; Shivani Mhatre; Cosmina Hogea; Annabel Lambert; Alex Busby; Naureen Starling
OBJECTIVES: To describe real-world treatment-related effects in patients with HER2-negative advanced (stage IIIA-IVB) gastric/gastroesophageal junction/esophageal adenocarcinoma (GC/GEJC/EAC) treated with first-line (1L) chemotherapy alone or chemotherapy plus immune checkpoint inhibitors (chemotherapy+ICI).
METHODS: Data were extracted from the Adelphi Real World Gastric Cancer Disease Specific Programme™, a cross-sectional survey, with retrospective data collection via medical chart review, of physicians and patients with advanced HER2-negative GC/GEJC/EAC in the United States, United Kingdom, Europe and Asia, from October 2022-September 2024. Patients were on 1L or second-line and beyond (2L+) treatment for advanced cancer at data collection. Physicians reported patient demographics, clinical characteristics and adverse events (AEs) for patients receiving 1L treatment from medical charts; patients self-reported AEs. For patients on 2L+ treatment, treatment duration and response on 1L was reported. Analyses presented here are descriptive.
RESULTS: Overall, 450 physicians provided data on 1623 patients on 1L (n=551 chemotherapy only; n=389 chemotherapy+ICI) and 643 patients on 2L+. AEs were reported for 47% and 38% of patients receiving 1L chemotherapy only and chemotherapy+ICI, respectively; commonly nausea (52%/46%) and diarrhea (22%/29%). Discrepancies were observed in most of physician-patient reported AEs; for instance, sleep disturbance was reported by 80%/72% of patients (chemotherapy only/chemotherapy+ICI) compared to only 7%/5% of physicians. Dose change was reported for 13%/14% of patients, mostly due to unacceptable tolerability (90%/89%). In the 2L+ treatment group [1L chemotherapy alone (n=311) or chemotherapy+ICI (n=74)], mean (SD) treatment duration was 6.2(3.2)/7.5(5.8) months, with complete or partial response experienced by 49% and 56% of patients, respectively.
CONCLUSIONS: In both treatment groups around half of patients experienced a complete or partial response and common AEs; indicating a need for novel treatments with improved response, and a safety profile that does not increase side effect burden. Physician-patient disconnect regarding AE reporting was observed, emphasising the need for better physician-patient communication.
METHODS: Data were extracted from the Adelphi Real World Gastric Cancer Disease Specific Programme™, a cross-sectional survey, with retrospective data collection via medical chart review, of physicians and patients with advanced HER2-negative GC/GEJC/EAC in the United States, United Kingdom, Europe and Asia, from October 2022-September 2024. Patients were on 1L or second-line and beyond (2L+) treatment for advanced cancer at data collection. Physicians reported patient demographics, clinical characteristics and adverse events (AEs) for patients receiving 1L treatment from medical charts; patients self-reported AEs. For patients on 2L+ treatment, treatment duration and response on 1L was reported. Analyses presented here are descriptive.
RESULTS: Overall, 450 physicians provided data on 1623 patients on 1L (n=551 chemotherapy only; n=389 chemotherapy+ICI) and 643 patients on 2L+. AEs were reported for 47% and 38% of patients receiving 1L chemotherapy only and chemotherapy+ICI, respectively; commonly nausea (52%/46%) and diarrhea (22%/29%). Discrepancies were observed in most of physician-patient reported AEs; for instance, sleep disturbance was reported by 80%/72% of patients (chemotherapy only/chemotherapy+ICI) compared to only 7%/5% of physicians. Dose change was reported for 13%/14% of patients, mostly due to unacceptable tolerability (90%/89%). In the 2L+ treatment group [1L chemotherapy alone (n=311) or chemotherapy+ICI (n=74)], mean (SD) treatment duration was 6.2(3.2)/7.5(5.8) months, with complete or partial response experienced by 49% and 56% of patients, respectively.
CONCLUSIONS: In both treatment groups around half of patients experienced a complete or partial response and common AEs; indicating a need for novel treatments with improved response, and a safety profile that does not increase side effect burden. Physician-patient disconnect regarding AE reporting was observed, emphasising the need for better physician-patient communication.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
RWD11
Topic
Real World Data & Information Systems
Disease
SDC: Oncology